Concorde Group to invest 50 mln euros in stem cell treatment centre
The new centre will be operated by the US company Healthcare of Today, through SK3 Group. The Concorde Group has secured its 50- million-euro investment both from own funds, as well as from private investors, from the European Community and from institutional investors. Concorde and Healthcare of Today formed a joint venture in order to build a stem cell treatment centre and a private luxury medical centre using the same technology. The research centre will have a total area of 20,000 square metres and treatment facilities covering 46,000 square metres.